Hydrolysis of b-lactam antibiotics by b-lactamase enzymes is the most common mechanism of bacterial resistance to these agents. Several small-molecule, mechanism-based inhibitors of b-lactamases such as clavulanic acid are clinically available although resistance to these inhibitors has been increasing in bacterial populations. In addition, these inhibitors act only on class A b-lactamases. Here we utilized phage display to identify peptides that bind to the class A b-lactamase, TEM-1. The binding af®nity of one of these peptides was further optimized by the synthesis of peptide arrays using SPOT synthesis technology. After two rounds of optimization, a linear 6-mer peptide with the sequence RRGHYY was obtained. A soluble version of this peptide was synthesized and found to inhibit TEM-1 b-lactamase with a K i of 136 mM. Surprisingly, the peptide inhibits the class A Bacillus anthracis Bla1 b-lactamase with a K i of 42 mM and the class C b-lactamase, P99, with a K i of 140 mM, despite the fact that it was not optimized to bind these enzymes. This peptide may be a useful starting point for the design of non-b-lactam, broad-spectrum peptidomimetic inhibitors of b-lactamases. Keywords: antibiotics/bacteriophage/inhibitors/peptide arrays
Introduction
The increased resistance of bacterial pathogens to clinically useful antibiotics has become a serious public health threat. It is therefore critical to identify new antimicrobials or to design inhibitors of antibiotic resistance-conferring enzymes. The b-lactam antibiotics such as the penicillins and cephalosporins are among the most often used antimicrobial agents. As with other antibiotics, resistance to these agents has been increasing in recent years. The most common mechanism of bacterial resistance to b-lactam antibiotics is the production of b-lactamases (Livermore, 1995) . These enzymes are secreted by both Gram-positive and Gram-negative bacteria and provide resistance by catalyzing the hydrolysis of the b-lactam ring that is common to all antibiotics of this class.
b-Lactamases have been grouped into four classes based on primary sequence homology. Classes A, C and D are active-site serine enzymes that catalyze the hydrolysis of the b-lactam via a serine-bound acyl intermediate (Ghuysen, 1991) . Class B enzymes require zinc for activity and catalysis does not proceed via a covalent intermediate (Car® et al., 1995; Bush, 1998; Wang et al., 1999) . The active-site serine b-lactamases belong to a larger family of penicillin-recognizing enzymes that includes the penicillin binding proteins (PBPs) that crosslink bacterial cell walls (Massova and Mobashery, 1998) . The most prevalent plasmid encoded b-lactamase in Gram-negative bacteria is the class A TEM-1 b-lactamase that catalyzes the hydrolysis of both penicillins and cephalosporins . Extended-spectrum cephalosporins have been introduced in an effort to circumvent the action of class A b-lactamases such as TEM-1. The use of these agents, however, has resulted in the emergence of TEM mutant derivatives capable of hydrolyzing extended spectrum antibiotics .
An alternative method to combat b-lactamase-mediated resistance has been the use of mechanism-based, smallmolecule inhibitors such as clavulanic acid and sulbactam (Bush, 2002) . These inhibitors protect the b-lactam drug from hydrolysis by b-lactamases and restore the therapeutic potential of the antibiotic (Charnas and Knowles, 1981; Bush, 2002) . Variants have now evolved, however, that resist these inhibitors while maintaining the ability to hydrolyze b-lactam antibiotics (Imtiaz et al., 1994; Henquell et al., 1995; Petrosino et al., 1998) . Therefore, a need exists for the development of new inhibitors.
Phage display is a powerful technique for studying protein± ligand interactions [reviewed by Smith and Petrenko (Smith and Petrenko, 1997) ]. The method involves the fusion of peptides or proteins to a coat protein of a ®lamentous bacteriophage (Smith, 1985) . The peptides or proteins are normally fused to the N-terminus of the gene III phage protein.
The gene III protein is a minor coat (3±5 copies per phage) protein located at the tip of the phage and is responsible for attachment of the phage to the bacterial F pilus in the course of the normal infection process (Rasched and Oberer, 1986) . Because the gene encoding the fusion protein is packaged within the same phage particle, there is a direct link between the phenotype, i.e. the ligand-binding characteristics of a displayed peptide and the DNA sequence of the gene for the displayed peptide. This permits large libraries of peptides of random amino acid sequence to be rapidly screened for desired ligand binding properties (Smith and Petrenko, 1997) .
Although phage display can be used to identify peptide ligands, these ligands generally do not bind the target protein with high af®nity except in cases where the protein normally functions in peptide recognition (Clackson and Wells, 1994; Cochran, 2001) . Peptide arrays offer a rapid means of optimizing the binding properties of peptides identi®ed using phage display (Reineke et al., 2001; Reimer et al., 2002) . The SPOT-synthesis method, for example, can be used to create large arrays of synthetic peptides on cellulose ®lters (Frank, 1992) . The method employs Fmoc protection chemistry whereby the reagents are delivered automatically to discrete spots on the ®lters (Reineke et al., 2001) . The resulting array can be screened directly in the solid phase using an appropriately labeled target protein to identify peptides that bind the target with increased af®nity (Reimer et al., 2002) .
A combination of phage display and SPOT synthesis were used here to identify and optimize peptides that bind and inhibit TEM-1 b-lactamase. Surprisingly, the peptides optimized for binding the TEM-1 enzyme also inhibited the class A Bacillus anthracis Bla1 enzyme and the class C b-lactamase P99. These broad-spectrum peptide inhibitors may serve as the basis for the design of peptidomimetics that inhibit a wide range of b-lactamases.
Materials and methods

Phage display
The Ph.D.-C7C library (New England Biolabs) was purchased and used to identify peptides that mediated binding to immobilized TEM-1 b-lactamase. The Ph.D.-C7C library consists of random sequence 7-mers fused to a minor coat protein (pIII) of M13 phage. Biopanning was performed by coating a micro-plate well with 200 ml of puri®ed TEM-1 b-lactamase at a concentration of 40 mg/ml in 0.1 M NaHCO 3 (pH 8.6) at 4°C overnight. The wells were then blocked with 200 ml of 5 mg/ml BSA in 0.1 M NaHCO 3 (pH 8.6), 0.02% NaN 3 . After blocking, the C7C phage were input at 2Q10 11 pfu/well in 200 ml of wash buffer [1Q TBS + 0.1% (v/v) Tween-20] and incubated at room temperature for 1 h. The wells were then washed 10 times with 200 ml of wash buffer to remove unbound phages and bound phages were eluted by the addition of 200 ml of 0.2 M glycine.HCl (pH 2.2) for 10 min at room temperature. The solution containing the eluted phages was neutralized by the addition of 25 ml of 1 M Tris, pH 8.0. The eluted phages were ampli®ed by adding 150 ml of the neutralized solution to 25 ml of Escherichia coli ER2738 cells [F¢ proA+B+ lacI q D(lacZ)M15 zzf::Tn10(Tet R )/ fhuA2 glnV D(lac-proAB) thi-1 D(hsdS-mcrB)5] (New England Biolabs) that had been grown to an OD 600 of 0.2 and incubating the culture at 37°C for 4.5 h. The phages were precipitated by the addition of 1/5 volume of 20% PEG/2.5 M NaCl and harvested by centrifugation. The titer of the resultant phage stock was determined by infecting E.coli ER 2738 cells with serial dilutions of the stock and counting the number of resultant plaques. The second and third rounds of biopanning were performed using the ampli®ed phage stocks from the previous round. The panning was identical except that the wash buffer for the second and third rounds was 1Q TBS + 0.5% Tween-20.
DNA sequencing was performed to determine if the library was converging on a particular sequence. For this purpose, 20 single plaques were selected after the ®rst round of panning and 40 plaques were selected following the third round of panning and single-stranded DNA was isolated and used as template for dideoxy DNA sequencing using the ±96 sequencing primer (5¢-CCCTCATAGTTAGCGTAACG-3¢). The DNA sequencing reactions were performed with the ABI Big Dye Terminator Kit and the sequences were resolved using an ABI 3100 automated DNA sequencer. Phage ELISA Phage stocks for ELISA experiments were prepared by adding 5 ml of phage supernatant from the clone of interest to a 25 ml culture of E.coli ER2738 that had been grown to an OD 600 of 0.1. The infected culture was then grown for 4.5 h at 37°C. The phages were harvested, precipitated and the titer was determined as described above. Wells of a micro-plate were coated with 20 mg/ml TEM-1 b-lactamase in 0.1 M NaHCO 3 , pH 8.6 with 200 ml per well at 4°C overnight and blocked with 200 ml of blocking buffer at room temperature for 1 h. Serial dilutions of the phage stock were performed into wash buffer (1Q TBS, 0.5% Tween-20) and 200 ml of each dilution were added to the coated wells. The wells were then washed six times with 200 ml of wash buffer. Phages that bound b-lactamase and were retained in the well were detected with an anti-M13 phage antibody conjugated to horseradish peroxidase (HRP) (Amersham). HRP was detected after the addition of the ABTS indicator reagent by monitoring the absorbance at 405 nm. Synthesis and screening of cellulose-bound peptides Cellulose-bound peptides were prepared by automated SPOT synthesis (Auto-Spot Robot ASP 222, Intavis, Bergisch Gladbach, Germany) as has been described in detail previously (Kramer et al., , 1999 Wenschuh et al., 2000) . Aminofunctionalized membranes were purchased from Intavis. The membranes are derivatized with a polyethylene glycol spacer with a length of 8±10 ethylene glycol units (Intavis). The spacer also contains a free amino group to initiate peptide synthesis. Peptide synthesis was performed with Fmocprotected amino acids as described previously (Wenschuh et al., 2000) .
Two methods were used for the detection of b-lactamase binding to the SPOT membranes. The ®rst method involved detection of bound TEM-1 b-lactamase using polyclonal antib-lactamase sera (data in Figure 3 ). For this experiment, the membrane was blocked overnight at 4°C with SuperBlock Buffer (Pierce) that was supplemented with 1 mg/ml bovine serum albumin (BSA) and 1 mg/ml casamino acids. The membrane was washed with 1Q TBS containing 1 mg/ml BSA and 1 mg/ml casamino acids (wash buffer) and TEM-1 b-lactamase was incubated with the membrane at 0.1 mg/ml in wash buffer at room temperature for 1 h. The membranes were washed four times with wash buffer for 10 min each and a 1:10 000 dilution of rabbit anti-b-lactamase serum in wash buffer was incubated with the membrane for 1 h at room temperature. Detection was performed using a donkey antirabbit IgG conjugated to HRP. Bound antibody was detected using Amersham ECL chemiluminescent substrate and X-ray ®lm.
For the second method, membranes were blocked overnight at 4°C with 1Q TBS containing 1 mg/ml BSA and 1 mg/ml casamino acids. After washing with 1Q TBS + 0.5% Tween-20, the membranes were incubated with 0.9 mg/ml TEM-1 b-lactamase conjugated to HRP for 2 h at room temperature. The membranes were then washed three times with 1Q TBS± Tween-20 and bound b-lactamase-HRP was detected by chemiluminescence using X-ray ®lm (ECL, Amersham) (data in Figure 4) . Quantitation of the intensity of spots was performed by densitometry using a VersaDoc Imaging System (Bio-Rad). Soluble peptide synthesis All soluble peptides with the exception of the protein kinase substrates were prepared by solid-phase peptide synthesis using Fmoc-protected monomers at the Baylor College of Medicine protein chemistry core facility using an ABI 433A synthesizer. The HSACSDTRRGDCG-NH 2 peptide was cyclized by the dropwise addition of ammonium hydroxide to the solution to pH 8.0. The progress of the reaction was monitored by reversed-phase high-performance liquid chromatography (RP-HPLC) and the ®nal product was puri®ed to >90% homogeneity by RP-HPLC. The HSAYSDTRRG-DYG-NH 2 , RRGHYY-NH 2 and AAGHYY-NH 2 peptides were puri®ed to >95% homogeneity by RP-HPLC. The identity of all synthesized peptides was veri®ed by electrospray mass spectrometry at the Baylor College of Medicine protein chemistry core facility. The protein kinase substrates LRRASLG-NH 2 and RRKASGP were purchased from American Peptide Company (Sunnyvale, CA). These peptides were puri®ed to >99% and were analyzed by mass spectrometry by American Peptide.
Puri®cation of b-lactamase proteins
The TEM-1 b-lactamase was puri®ed to >90% homogeneity using a zinc chelating Sepharose (fast¯ow) column (Pharmacia) and Sephadex G-75 gel ®ltration chromatography as described previously (Cantu et al., 1996) . The P99, Bla1 and IMP-1 enzymes were expressed in E.coli and puri®ed as described previously (Materon and Palzkill, 2001; Zhang et al., 2001; Materon et al., 2003) .
b-Lactamase inhibition assays
Inhibition assays were performed as described previously (Petrosino et al., 1999; Rudgers et al., 2001) . Brie¯y, various concentrations of peptide were incubated with TEM-1 (45 nM), Bla1 (0.9 nM), P99 (0.6 nM) or IMP-1 (0.8 nM) b-lactamase for 1 h in 50 mM phosphate buffer (pH 7.0) containing 1 mg/ml BSA. Following the incubation, the b-lactam substrate cephalosporin C (TEM-1, P99) or phenoxymethylpenicillin (Bla1) or nitroce®n (IMP-1) was added at a concentration at least 10-fold lower than the K m of the substrate for the b-lactamase being tested. Hydrolysis of cephalosporin C was determined spectrophotometrically by measuring the decrease in A 280 (De = 2390 M ±1 cm ±1 ). Hydrolysis of phenoxymethylpenicillin (Pen V) by Bla1 was monitored by measuring the decrease in A 240 (De = 570 M ±1 cm ±1 ). Hydrolysis of nitroce®n was monitored by measuring the increase in A 495 (De = 15 000 M ±1 cm ±1 ). The concentration of peptide that reduced enzyme velocity by half was the IC 50 value. The K i value was calculated from the IC 50 using the method of Cheng and Prusoff (Cheng and Prusoff, 1973) (Cheng and Prusoff, 1973) . The data were ®tted to determine the IC 50 value using GraphPad Prism software.
The mode of inhibition of the RRGHYY-NH 2 peptide was determined using a Beckman DU-640 spectrophotometer in 50 mM potassium phosphate (pH 7) containing 1 mg/ml BSA in a ®nal volume of 0.5 ml. All assays were performed in triplicate. Hydrolysis of cephalosporin C by TEM-1 and P99 and hydrolysis of Pen V by Bla1 was determined spectrophotometrically at 280 and 240 nm, respectively, using the molar absorbances given above. The peptide was allowed to incubate with TEM-1, P99 or Bla1 for 1 h prior to the addition of cephalosporin C (TEM-1, P99) or Pen V (Bla1). TEM-1 (45 nM) and P99 (5 nM) assays were carried out at 0, 50 and 100 mM RRGHYY-NH 2 and increasing concentrations of cephalosporin C. Bla1 (0.9 nM) assays were carried out at 0, 15, 30 mM RRGHYY-NH 2 and increasing concentrations of Pen V. K m and V max values were determined from double reciprocal plots at each concentration of RRGHYY-NH 2 .
Results
Selection of b-lactamase-binding peptides
The goal of these experiments was to perform an unbiased search to identify peptides from a random sequence library that would bind to the active site of TEM-1 b-lactamase. For this purpose, a phage display library displaying randomized 7-mer peptides¯anked by a pair of cysteine residues was enriched for phage particles that bind to immobilized TEM-1 b-lactamase. After extensive washing to remove unbound phage, the bound phages were eluted from the immobilized b-lactamase and used to infect E.coli. The phages were ampli®ed in the infected bacteria and used for another round of binding enrichment. After each round of binding enrichment, representative clones were randomly selected for DNA sequencing to determine if the library was converging on a particular sequence. After three rounds of panning, phages displaying six different peptide sequences were discovered (Figure 1 ). Among these, phages displaying the sequence CSDTRRGDC were predominant, suggesting that this is the optimal peptide ligand for b-lactamase binding.
Phage ELISA was used to verify that the CSDTRRGDC peptide identi®ed by the phage display experiments bound to immobilized TEM-1 b-lactamase (Huang et al., 1998) (Figure 2 ). For these experiments, 10 11 phages displaying the CSDTRRGDC peptide were added to a microtiter well that had been coated with 20 mg/ml TEM-1 b-lactamase. After extensive washing, bound phages were detected with an anti-M13 phage antibody. Phages displaying two additional sequences, CKLGPIRGC and CLTSHNMMC, were also assayed for binding ( Figure 1 ). As a negative control, the phages were also tested for binding to the E.coli maltose binding protein (MBP). The results are consistent with the DNA sequencing results in that the CSDTRRGDC peptide exhibited the strongest binding to b-lactamase (Figure 2 ). Phages displaying each of the Broad-spectrum peptide inhibitor of b-lactamase peptides gave ELISA signals higher than background binding to MBP, suggesting that all three peptides bind speci®cally to TEM-1 b-lactamase.
Although the CSDTRRGDC peptide was selected based on the ability to bind TEM-1 b-lactamase, it is possible that the peptide could bind without inhibiting function. To establish if the peptide inhibits TEM-1 b-lactamase, the peptide HSACSDTRRGDCG-NH 2 , which contains the 7-mer in addition to¯anking sequences from the phage, was synthesized, oxidized and the disul®de-bonded version was puri®ed. This peptide was used in a b-lactamase inhibition assay (Rudgers et al., 2001 ) and found to inhibit TEM-1 b-lactamase very weakly with a K i of~3.5 mM. Therefore, although the peptide bound and inhibited the enzyme, it clearly needed further optimization to be a viable inhibitor or lead peptide.
SPOT synthesis
The SPOT synthesis method can be used to synthesize large arrays of synthetic peptides on planar cellulose supports (Frank, 1992; Reineke et al., 2001) . This technique was used to synthesize an array of peptides containing all possible single amino acid substitutions for the 7-mer sequence and thē anking cysteines in the HSACSDTRRGDCG peptide. The array was screened for peptides that bound TEM-1 b-lactamase by incubating the ®lter with puri®ed, soluble TEM-1 b-lactamase. After extensive washing, b-lactamase that was retained on the ®lter was detected with an anti-b-lactamase polyclonal antibody in a format similar to western blotting ( Figure 3) . The results indicated that the SDT region of the CSDTRRGDC sequence did not contribute to binding since all substitutions function equally well at these positions. In contrast, the arginine residues appear to be critical for binding of the peptide to b-lactamase since substitutions at these positions eliminate binding (Figure 3 ). In addition, the disul®de bond, which constrains the peptide, does not appear important for binding. In fact, a substitution of the C-terminal cysteine with tyrosine appears to increase binding strength of the peptide to b-lactamase (Figure 3) . Similarly, certain substitutions at the C-terminal glycine and aspartate positions of the CSDTRRGDC result in increased binding to b-lactamase.
In order to test whether substitution of the cysteine residues increases binding af®nity as suggested by the array results, a soluble peptide was synthesized with the cysteines replaced by tyrosine residues. The HSAYSDTRRGDYG-NH 2 peptide was found to inhibit TEM-1 b-lactamase with a K i of 298 mM (Table I) . Therefore, replacement of the cysteine residues with tyrosines results in an~10-fold increase in binding af®nity, which is consistent with the qualitative result from the SPOT array.
Peptide binding to b-lactamase was optimized further by synthesis of another SPOT array. The previous array suggested that only the RRGDYG region of the peptide contributed to b-lactamase binding. In addition, the results of the previous array suggested that substitution of the aspartate residue (RRGDYG) with histidine to give a peptide with the sequence RRGHYG would result in improved binding. Therefore, the RRGHYG peptide and all single amino acid substitutions of this peptide were synthesized on the SPOT array (Figure 4) . To ensure that the histidine substitution does in fact result in tighter binding, the RRGDYG peptide was also synthesized on the array for comparison. The array was probed with puri®ed TEM-1 b-lactamase that had been conjugated to HRP, which allowed for direct detection of binding upon addition of the chemiluminescent HRP substrate. As predicted based on the results of the previous array, the RRGHYG peptide gave a stronger binding signal than the RRGDYG control peptide ( Figure 4) . The results also indicated that the two N-terminal arginine residues are important for binding to b-lactamase in that only arginine or lysine residues can substitute at these positions. In contrast, the glycine residue at position three (RRGHYG) can be substituted by all but negatively charged amino acids. Similarly, the histidine residue at position four (RRGHYG) can also be substituted by several different amino acids but not by negatively charged residues. Several different residues can substitute for the tyrosine at position ®ve (RRGHYG), although many of these substitutions, particularly negatively charged residues, result in less effective binding than the peptide containing tyrosine at this position. Finally, several amino acids, including tyrosine, when substituted for glycine at position six (RRGHYG) result in a more intense spot and presumably tighter binding. In summary, the SPOT synthesis results indicate a 6-mer peptide can bind to TEM-1 b-lactamase and that the N-terminal arginine residues are critical for this binding. The soluble RRGHYY-NH 2 peptide was synthesized and tested for inhibition of TEM-1 b-lactamase to validate the SPOT synthesis results. This peptide includes the substitution of tyrosine for glycine at position six, which appears to contribute to tighter binding based on the array results (Figure 4) . The peptide was found to inhibit TEM-1 b-lactamase with a K i of 136 mM, which is an~2-fold improvement in af®nity relative to the HSAYSDTRRGDYG-NH 2 peptide and a 25-fold improvement relative to the disul®de-bonded HSACSDTRRGDCG-NH 2 peptide originally discovered by phage display (Table I) .
The SPOT synthesis results suggest the arginine residues within the RRGHYY peptide play an important role in b-lactamase binding. This result was con®rmed by determining the inhibition constant for the soluble peptide AAGHYY-NH 2 . Substitution of the arginines with alanine residues resulted in a 3-fold increase in K i for inhibition of TEM-1 b-lactamase, indicating that they contribute to inhibition (Table I) .
Because the arginine residues are important for binding, the ability of soluble L-arginine to inhibit TEM-1 b-lactamase was assayed. Soluble L-arginine at concentrations up to 2.5 mM had no effect on b-lactamase activity, indicating that L-arginine is not an inhibitor of the enzyme. In order to address the possibility that the dipeptide Arg±Arg could inhibit the enzyme, an Arg±Arg-NH 2 peptide was tested and found to have no effect on b-lactamase activity at concentrations up to 2.0 mM. Therefore, although the Arg±Arg region of the peptide appears important for binding b-lactamase, it is not suf®cient. It is possible, however, that the presence of the Arg±Arg motif in the context of a peptide of similar size to RRGHYY-NH 2 is suf®cient for inhibiting b-lactamase. This possibility was tested using the commercially available protein kinase substrates LRRASLG-NH 2 and RRKASGP (Kemp et al., 1977; Pomerantz et al., 1977) . It was found that these peptides had no effect on TEM-1 b-lactamase activity at concentrations up to 4 mM. Therefore, the speci®c sequence of the RRGHYY-NH 2 peptide appears important for inhibition.
Inhibition of other b-lactamases
Although the peptides were selected and optimized for binding to the TEM-1 b-lactamase of Gram-negative bacteria, it is possible these peptides may also inhibit other b-lactamases. Recently, the gene encoding the Bla1 class A b-lactamase from B.anthracis was cloned and the enzyme was expressed and puri®ed from E.coli (Chen et al., 2003; Materon et al., 2003) . The HSAYSDTRRGDYG-NH 2 and RRGHYY-NH 2 peptides were tested for inhibition of the B.anthracis Bla1 enzyme (Table I) . Surprisingly, despite having been optimized to bind TEM-1 b-lactamase, each of the peptides was a more effective inhibitor of the Bla1 enzyme than the TEM-1 enzyme. For example, the RRGHYY-NH 2 peptide inhibits Bla1 with a K i of 42 mM, which is~3-fold lower than the K i for inhibition of TEM-1 b-lactamase. Similarly, the HSAYSDTRRGDYG-NH 2 peptide inhibits Bla1 with a K i of 70 mM, which is~4-fold lower than the K i for inhibition of TEM-1 b-lactamase. A possible explanation for the broad inhibition pro®le of these peptides is that the catalytic residues in the active site pocket of class A enzymes such as TEM-1 and Bla1 are highly conserved . Thus, although the enzymes are only about 30% identical, the active site pockets are very similar.
The peptides were also tested for inhibition of the class C b-lactamase, P99, from the Gram-negative bacterium Enterobacter cloacae (Lobkovsky et al., 1993; Dubus et al., 1996) . The class A and class C enzymes have a similar fold and contain conserved amino acids that act similarly in catalysis (Lobkovsky et al., 1993) . However, there are also many differences in the active site, which may explain why the mechanism-based inhibitors sulbactam and clavulanic acid are poor inhibitors of class C enzymes (Bush, 2002) . Although the HSACDTRRGDCG-NH 2 peptide did not detectably inhibit P99 at concentrations up to 800 mM, the HSAYDTRRGDYG-NH 2 peptide inhibited P99 with a K i of 254 mM and the RRGHYY-NH 2 peptide inhibited the enzyme with a K i of 140 mM. Therefore, the RRGHYY-NH 2 peptide inhibits class A and class C enzymes with similar ef®ciency.
Because the RRGHYY-NH 2 peptide inhibited several enzymes, the speci®city of these interactions was investigated further. The replacement of the arginines with alanines in the AAGHYY-NH 2 peptide resulted in a 3-fold increase in K i for the P99 enzyme and a 2-fold increase for Bla1, indicating that the arginine residues are important for binding both of these enzymes (Table I ). In addition, it was found that, similarly to the results with TEM-1, the dipeptide Arg±Arg-NH2 had no effect on the b-lactamase activity of these enzymes at concentrations up to 2.0 mM (Table I) . These results suggest that the sequence requirements of the peptide for inhibition of the b-lactamases are similar. Because the arginine residues are important for inhibition, it is possible that a charge interaction contributes to binding. However, there is no correlation between binding and the pI of the enzyme in that the pI of TEM-1 is 5.4 whereas those of Bla1 and P99 are 9.1 and 8.7, respectively. Broad-spectrum peptide inhibitor of b-lactamase Finally, it was found that the RRGHYY-NH 2 peptide displayed no inhibition of the class B zinc-metallo-b-lactamase IMP-1 at concentrations up to 400 mM. This result is not surprising in that the zinc metallo-enzymes have a completely different fold and utilize zinc ions rather than a catalytic serine (Wang et al., 1999) . Taken together, these results suggest the RRGHYY-NH 2 peptide is a broad-spectrum inhibitor of activesite serine b-lactamases and that this inhibition is dependent on the speci®c sequence of the peptide.
Mode of RRGHYY-NH 2 inhibition
In order to gain further insight into the mechanism by which the RRGHYY-NH 2 peptide inhibits b-lactamases, the inhibition patterns with respect to the TEM-1, Bla1 and P99 enzymes were determined. The RRGHYY-NH 2 peptide demonstrated a competitive inhibition pattern with respect to b-lactam substrates for each of the enzymes tested ( Figure 5 ). This inhibition pattern suggests that the peptide acts similarly for each target by binding at or near the active site of the b-lactamases to block entry of the b-lactam substrate.
Discussion
Phage display has been shown to be an effective means of sorting large collections of random sequence peptides for variants that bind a target protein (Smith and Petrenko, 1997).
Here we sorted a library of random 7-mers¯anked by cysteine residues for peptides that could bind TEM-1 b-lactamase. From the panning results, a total of six different peptide sequences were identi®ed. Of these selected peptides, the CSDTRRGDC sequence was identi®ed multiple times and ELISA experiments con®rmed that phage displaying this peptide bound to TEM-1 b-lactamase. A soluble peptide containing this sequence and also¯anking sequence from the phage (HSACSDTRRGDCG-NH 2 ), however, inhibited b-lactamase very poorly.
SPOT synthesis was used to create peptide arrays to identify peptide variants that exhibit higher af®nity for TEM-1 b-lactamase. SPOT synthesis permits rapid highly parallel synthesis of hundreds to thousands of peptides (Frank, 1992; Reineke et al., 2001) . Furthermore, because the peptides are synthesized in an array format on a cellulose ®lter, it is straightforward to screen the array to identify peptides that bind a target protein. The method has been used extensively to map antigen±antibody interactions and other types of protein± protein interactions (Kramer et al., 1997; Knoblauch et al., 1999; Reineke et al., 2001) . It has also been used to design a substrate-derived peptide that inhibits protein kinase G with a K i of 7.5 mM and inhibits protein kinase A with a K i of 750 mM (Dostmann et al., 1999) . In our study, SPOT synthesis provided rapid information concerning which amino acids make the most critical contributions to binding b-lactamase. This information was used to design a peptide that binds TEM-1 b-lactamase with 25-fold higher af®nity and is also reduced in size relative to the starting peptide identi®ed by phage display.
In aqueous solution, peptides may assume multiple conformations, some of which may be favorable for binding to the target substrate. The lack of a ®xed structure, however, for entropic reasons lowers the af®nity of the peptide for the target protein (Cochran, 2001) . The conformational¯exibility of the peptide also obscures any connection between its solution properties and the active, bound conformation. Because of this, phage display libraries are often designed with cysteines anking the peptide to be displayed (Wrighton et al., 1996) . Because the gene III protein is secreted to the oxidative environment of the periplasm, cysteine residues within a single displayed peptide can be expected to form intrapeptide disul®des in at least a portion of the displayed peptides (Smith and Petrenko, 1997) . A disul®de-constrained random 7-mer library was used here in an attempt to identify tightbinding peptides. Sequencing of clones selected by biopanning identi®ed a peptide that was subsequently con®rmed to bind immobilized b-lactamase by phage ELISA. The soluble peptide containing the disul®de bond, however, was a surprisingly poor inhibitor of TEM-1 b-lactamase with a K i in the millimolar range. Synthesis of a peptide that replaced the cysteines with tyrosine residues bound much tighter, suggesting that the disul®de bond constrained the peptide in a conformation that was not optimal for binding. Why was this peptide selected as a binder in the phage display experiments? One possibility is that there is not a disul®de-constrained peptide in the library that is capable of binding tightly to blactamase and the selected peptide, albeit a weak binder, is nevertheless one of the best available in the library. Another possibility is that there is a mixture of oxidized and reduced peptides displayed on each phage particle and the binding of the reduced, linear peptide to the immobilized protein is responsible for the enrichment of the clone in biopanning. Regardless of the mechanism, it is clear that a disul®de-constrained version of a peptide is not necessarily the optimal binder.
An interesting property of the RRGHYY-NH 2 peptide is that, despite the fact that it was selected and optimized only for TEM-1 b-lactamase binding, it also inhibits the class B.anthracis Bla1 enzyme and the class C P99 b-lactamase. The identi®cation of an inhibitor of the Bla1 enzyme is of particular signi®cance in light of the threat of bioterrorism in addition to the agricultural implications that B.anthracis presents to livestock. Antibiotics of choice for the treatment of anthrax include tetracyclines (e.g. doxycycline), macrolides (e.g. erythromycin), quinolones (cipro¯oxacin) and b-lactams (e.g. penicillin). Cavallo et al. tested 96 isolates of B.anthracis for their susceptibilities to 25 different antibiotics and found that 11.5% of the isolates conferred resistance to b-lactam antibiotics penicillin G and amoxicillin, most likely owing to the presence of a b-lactamase enzyme(s) (Cavallo et al., 2002) . Further development of the RRGHYY-NH 2 peptide into a peptidomimetic could result in a useful inhibitor for the class A Bla1 enzyme. Because B.anthracis does not possess an outer membrane, a peptide-derived inhibitor would have access to secreted enzymes such as b-lactamase. In fact, with a molecular weight of 850, the RRGHYY-NH 2 peptide is already signi®cantly smaller than vancomycin, a glycopeptide antibiotic commonly used to treat Gram-positive bacterial infections, which has a molecular weight of 1400 (Nieto and Perkins, 1971) .
It is of interest that the RRGHYY-NH 2 peptide is 50% identical with a type II¢ b-turn sequence found in the b-lactamase inhibitory protein (BLIP). BLIP is a 165 amino acid protein produced by Streptomyces clavuligerus that binds and inhibits TEM-1 b-lactamase with a K i of 0.1±0.6 nM (Strynadka et al., 1994; Petrosino et al., 1999) . The b-turn encompasses residues 46-AAGDYY-51 and was found in the co-crystal structure of the BLIP±b-lactamase complex to insert into the active site of b-lactamase (Strynadka et al., 1996) . Based on this observation, a soluble peptide with the sequence CAAGDYYC was previously synthesized and found to inhibit TEM-1 b-lactamase with a K i of 600 mM when oxidized and 490 mM when reduced (Rudgers et al., 2001 ). The 490 mM K i value of the reduced CAAGDYYC is similar to the 438 mM K i determined here for the AAGHYY-NH 2 peptide (Table I ). Hence, it is possible that the RRGHYY-NH 2 peptide binds in a similar manner to the BLIP b-turn with the arginine residues providing increased af®nity. This, in turn, suggests that the phage display and SPOT synthesis optimization methods converged on a similar b-lactamase-binding peptide to that which has evolved on BLIP.
An interesting question is how the RRGHYY-NH 2 peptide is capable of inhibiting three separate b-lactamases. The active site pockets of the TEM-1 and Bla1 enzymes are similar, hence many common interactions may occur between the peptide and these class A enzymes. The P99 b-lactamase, however, is a class C enzyme that possesses a similar overall fold to the class A enzymes but several differences in the active site region (Lobkovsky et al., 1993) . The¯exibility of the non-constrained RRGHYY-NH 2 peptide may contribute to the broad speci®-city. A non-constrained ligand can more easily adapt to altered binding sites than a conformationally constrained ligand (Ren et al., 2000) . It is of interest in this regard that the BLIP-based CAAGDYYC peptide described above does not inhibit the P99 enzyme when oxidized but when reduced inhibits P99 with a K i of 135 mM (Rudgers et al., 2001) . This result supports a role for exibility in binding. A detailed understanding of the mechanism of broad binding speci®city, however, awaits structural information on the peptide±enzyme complexes.
